Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nrf2 transcript and oligomers levels correlated with PD duration.
|
31682033 |
2020 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation.
|
30296616 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we found that DDO-7263, a novel Nrf2-ARE activator reported by us, has ideal therapeutic effects on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease in mice.
|
30615919 |
2019 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MPTP-induced PD mice showed decreased expression of nuclear factor erythroid 2-related factor (Nrf2) and its target phase II genes in gastric and colon neuromuscular tissues.
|
31187328 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that activation of nuclear factor erythroid 2-related factor 2/heme oxygenase-1 (Nrf2/HO-1, potential therapeutic targets for neurodegeneration) with gintonin could abrogate PD-associated neurotoxicity by modulating the accumulation of α-synuclein, neuroinflammation, and apoptotic cell death in an MPTP/MPP<sup>+</sup> models of PD.
|
29675576 |
2019 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These neuritic defects result from impaired Nrf2 activity on antioxidant response elements (AREs) localized to a microtubule-associated protein (Map1b) gene enhancer and are rescued by forced expression of Map1b as well as by both Nrf2 overexpression and pharmaceutical activation in PD neurons.
|
31235589 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously isolated 2',3'-dihydroxy-4',6'-dimethoxychalcone (DDC) from green perilla leaves as an activator of the nuclear factor erythroid 2-related factor-2 (Nrf2)-antioxidant response element (ARE) and demonstrated the protective effects of DDC both in vitro and in vivo in PC12 cells and Parkinson's disease models, respectively.
|
31462615 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The damaged function and altered localization of NRF2 are found in most neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis.
|
30617737 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, Nrf2-dependent HO-1 signaling activation represents a potential preventive and therapeutic target in Parkinson's disease management.
|
31757050 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, this study demonstrates NAR enhanced astroglial neurotrophic effects on DA neurons through the regulation of Nrf2 activation, and these findings might open new potential promising avenues for neurotrophic factor-based treatment of PD.
|
30527894 |
2019 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Indeed, altered Nrf2 activity is involved in aging and NDD, such as AD and PD.
|
31415806 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously synthesized and reported a novel vinyl sulfone (<b>1</b>) as an Nrf2 activator with therapeutic potential for Parkinson's disease (PD).
|
31312409 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, 17e is a novel Nrf2 activator with excellent druglike properties and represents a potential therapeutic candidate for PD.
|
30540174 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these datasets show that the Nrf2-ARE pathway mediates the protective effects of hydralazine on Parkinson's disease.
|
30949126 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neuroprotection of Indole-Derivative Compound NC001-8 by the Regulation of the NRF2 Pathway in Parkinson's Disease Cell Models.
|
31781339 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
All this makes Nrf2 an optimal target for drugs that could support the mitochondrial quality control, which, in combination with antioxidant protection, can significantly slow down the pathogenesis of PD.
|
30617864 |
2019 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that CO released by CORM-2 treatment may have protective effects against oxidative cell death in PD through the potentiation of cellular adaptive survival responses via activation of Nrf2 and upregulation of heme oxygenase-1, leading to increasing antioxidant defense capacity.
|
29429149 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neuroprotective Effects of a Traditional Multi-Herbal Medicine Kyung-Ok-Ko in an Animal Model of Parkinson's Disease: Inhibition of MAPKs and NF-κB Pathways and Activation of Keap1-Nrf2 Pathway.
|
30618742 |
2018 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear factor-E2-related factor 2 (NRF2) is a transcription factor that activates the antioxidant cellular defense in response to oxidative stress, leading to neuroprotective effects in Parkinson's disease (PD) models.
|
30315936 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pinostrobin Exerts Neuroprotective Actions in Neurotoxin-Induced Parkinson's Disease Models through Nrf2 Induction.
|
29961319 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study provides support for the involvement of both NFE2L2 and PPARGC1α in PD susceptibility and progression, marginally and through pathways involving MB/PQ exposure.
|
29630901 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway is a well-established antioxidant pathway in various diseases such as diabetes, renal disease, various neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, etc.
|
29447051 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several studies suggest that an increase of glutathione (GSH) through activation of the transcriptional nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in the dopaminergic neurons may be a promising neuroprotective strategy in Parkinson's disease (PD).
|
29307179 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
As such, Nrf2 deregulation has been linked to both aging and pathogenesis of many human chronic diseases, including neurodegenerative ones such as Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis.
|
29969760 |
2018 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, the expression of Nrf2 and HO-1 was up-regulated by LPS only in young LPS-PD mice, but not in aged mice.
|
30271656 |
2018 |